高C反应蛋白与白蛋白比值预示结外自然杀伤T细胞淋巴瘤的临床预后较差。
High C-Reactive Protein to Albumin Ratio Predicts Inferior Clinical Outcomes in Extranodal Natural Killer T-Cell Lymphoma.
作者信息
Di Quan-Shu, Xu Tao, Song Ying, Zuo Zhi-Gang, Cao Feng-Jun, Yu Xiong-Jie, Tang Ji-Ying, Zhang Wei, Li Chen, Wan Guo-Xing, Cai Xiao-Jun
机构信息
Department of Oncology, Renmin Hospital, Hubei, China.
Laboratory of Medicinal Plant, Institute of Basic Medical Sciences, School of Basic Medicine, Hubei University of Medicine, Shiyan, Hubei, China.
出版信息
Dose Response. 2020 Apr 7;18(2):1559325820917824. doi: 10.1177/1559325820917824. eCollection 2020 Apr-Jun.
OBJECTIVE
The prognostic value of C-reactive protein to albumin ratio (CAR) has been identified in several cancers but not in extranodal natural killer T-cell lymphoma (ENKTL) as yet. We aimed to evaluate the prognostic value of CAR in ENKTL.
METHODS
A retrospective study with 246 patients with ENKTL was performed to determine the prognostic value of pretreatment CAR and examine the prognostic performance of CAR incorporating with International Prognostic Index (IPI) or natural killer/T-cell lymphoma prognostic index (NKPI) by nomogram.
RESULTS
The Cox regression analyses showed that high CAR (>0.3) independently predicted unfavorable progression-free survival (PFS, = .011) and overall survival (OS, = .012). In the stratification analysis, the CAR was able to separate patients into different prognoses regarding both OS and PFS in Ann Arbor stage I+II as well as III+IV, IPI score 0 to 1, and NKPI score 1 to 2 subgroups (all < .05). Additionally, the predictive accuracy of the IPI-based nomogram incorporating CAR, albumin to globulin ratio (AGR), and IPI for OS and PFS appeared to be lower than the NKPI-based nomogram incorporating CAR, age, AGR, extranodal site, and NKPI.
CONCLUSION
Pretreatment CAR is a simple and easily accessible parameter for independently predicting OS and PFS in patients with ENKTL.
目的
C反应蛋白与白蛋白比值（CAR）的预后价值已在多种癌症中得到确认，但在结外自然杀伤T细胞淋巴瘤（ENKTL）中尚未得到确认。我们旨在评估CAR在ENKTL中的预后价值。
方法
对246例ENKTL患者进行回顾性研究，以确定治疗前CAR的预后价值，并通过列线图检验CAR与国际预后指数（IPI）或自然杀伤/T细胞淋巴瘤预后指数（NKPI）相结合的预后性能。
结果
Cox回归分析显示，高CAR（>0.3）独立预测无进展生存期（PFS， = 0.011）和总生存期（OS， = 0.012）不良。在分层分析中，CAR能够将Ann Arbor分期I+II以及III+IV、IPI评分0至1和NKPI评分1至2亚组的患者按OS和PFS分为不同预后（均 < 0.05）。此外，基于IPI并纳入CAR、白蛋白与球蛋白比值（AGR）和IPI的列线图对OS和PFS的预测准确性似乎低于基于NKPI并纳入CAR、年龄、AGR、结外部位和NKPI的列线图。
结论
治疗前CAR是独立预测ENKTL患者OS和PFS的一个简单且易于获取的参数。
Zotero 插件